Loading...
•
Dec 31, 2020
ANI Pharmaceuticals Q4 2020 Earnings Report
ANI Pharmaceuticals reported fourth quarter and full year 2020 results, positioning the company for sustainable future growth.
Key Takeaways
ANI Pharmaceuticals reported Q4 2020 net revenues of $57.3 million, a net loss of $3.6 million, and a diluted loss per share of $0.30. The company's adjusted non-GAAP diluted EPS was $0.80. ANI is focused on sustainable future growth and has strengthened its capital structure through the acquisition of Novitium Pharma.
Net revenues for Q4 2020 were $57.3 million.
Net loss for Q4 2020 was $3.6 million, with a diluted loss per share of $0.30.
Adjusted non-GAAP diluted EPS for Q4 2020 was $0.80.
A definitive agreement to acquire Novitium Pharma was made to strengthen R&D and expand generics and CDMO business.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Brands Revenue
CapyFin.comGeneric Pharmaceutical Products Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income